Search clinical trials for: Sym004 (9/6 mg/kg)

Total 1266 results

BioMarin Pharmaceutical

Terminated

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Italy, Sweden
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Sameem M. Abedin, MD

Recruiting

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

Graft-versus-host Disease

United States
Annick Desjardins
Symphogen A/S

Completed

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Malignant Glioma

United States
EMD Serono

Terminated

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Germany
Symphogen A/S

Completed

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France, Spain, United States, Belgium, Germany, Italy, Russian Federation, Hungary, Poland, Austria
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
Daiichi Sankyo, Inc.

Completed

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Liver Neoplasms | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer

Korea, Republic of, Taiwan, United States, Japan
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Terminated

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Asthma

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
JW Pharmaceutical

Recruiting

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients (EPIC)

Gout

Korea, Republic of
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Eisai Inc.
Dr. Reddy's Laboratory; Citius Pharmaceuticals

Completed

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Persistent or Recurrent Cutaneous T-Cell Lymphoma

United States, Australia, Puerto Rico
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Proven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
ViGenCell Inc.

Not yet recruiting

A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

Graft Versus Host Disease
Merck Sharp & Dohme LLC

Terminated

Treatment With Infliximab in a Medical Setting (Study P05587) (OPTIMIST)

Crohn's Disease
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Janssen Research & Development, LLC

Terminated

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
Merck Sharp & Dohme LLC

Completed

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Staphylococcal Infection
University of Texas Southwestern Medical Center
GlaxoSmithKline

Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
Max Dieterich
University of Rostock

Completed

Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty

Surgical Side Infections After Breast Reduction

Germany
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Medical College of Wisconsin
Miltenyi Biomedicine GmbH

Active, not recruiting

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Changhai Hospital
The Second Hospital of Hebei Medical University; Zhejiang University; Qinghai... and other collaborators

Completed

9 Minutes for Tandem Colonoscopy Withdrawal

Colorectal Adenoma | Colon Polyp

China
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Changhai Hospital
Shaanxi Provincial People's Hospital; Qinghai People's Hospital; The First Affiliated... and other collaborators

Completed

9 Minutes for Colonoscopy Withdrawal

Colon Polyps | Colorectal Adenomas

China
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel

Search clinical trials for: Sym004 (9/6 mg/kg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations